Exclusive Summary

• • Patent long expired and US-registered, enabling rapid multi-country distribution entry; • Listed on WHO EML and guideline-supported for OR/ICU use, serving ~330M surgeries/year plus severe ARDS needs; • Full lineup including 200mg/20mL high-strength vial optimizes ICU infusions, cutting fluid load and handling; • US FDA registration and robust sterile injectable quality systems support compliant dossiers and reliable cold-chain; • Typically 50–80% cheaper than brand, delivering strong value in hospital tenders and group purchasing.